首页 | 本学科首页   官方微博 | 高级检索  
   检索      

贝伐单抗辅助的23G玻璃体切割术治疗严重增生性糖尿病视网膜病变的疗效观察
引用本文:李涛,郑志,郑冰清,赵淑芝,陈威,倪丽莎.贝伐单抗辅助的23G玻璃体切割术治疗严重增生性糖尿病视网膜病变的疗效观察[J].现代生物医学进展,2013(23):4488-4491.
作者姓名:李涛  郑志  郑冰清  赵淑芝  陈威  倪丽莎
作者单位:上海交通大学附属第一人民医院眼科,上海200080
基金项目:国家973专项前期(2010cB535006);国家自然基金面上项目(81070739)
摘    要:目的:2011年,我国糖尿病患者人数高达9240万。糖尿病视网膜病变(diabeticretinopathy,DR)作为糖尿病患者的常见并发症,在糖尿病人群中的患病率为37%,是导致成人获得性盲的最主要原因之一。严重增生性糖尿病视网膜病变以牵拉性视网膜脱离、玻璃体出血为特征,具有致盲率大,手术难度高等特点。针对与此,本文主要探讨术前注射贝伐单抗对23G玻璃体切割手术治疗严重增生性糖尿病视网膜病变患者效果的影响。方法:回顾性病例对照研究。共收集严重增生性糖尿病视网膜病变患者70例,药物辅助手术组(A组)21例,术前3—7天行玻璃体腔注射贝伐单抗(1.25mg/O.05mL);单纯手术组(B组)49例,行23G玻璃体切割术。分析两组术前及术后视力、手术时间、医源性裂孔、电凝、术后出血的不同。结果:在术后3月,两组视力提高有统计学意义(P〈O.05)。A组平均手术时间为74分钟,而B组平均手术时间为85分钟(P〉0.05)。医源性裂孔在A组中有1例,而B组中有16例(P〈0.05),在A组中有3例使用电凝,B组中有25例使用电凝(P〈0.05)。A组有1例出现术中及术后出血,B组为20例(P〈O.05)。结论:在这个回顾性研究中,我们发现对于严重增生性糖尿病视网膜病变的病人,术前玻璃体腔注射1.25mg/O.05ml贝伐单抗可以显著减少医源性裂孔的发生,减少术中电凝使用及术中术后出血的发生。

关 键 词:贝伐单抗  阿伐斯汀  严重增生性糖尿病视网膜病变  药物辅助玻璃体手术  手术效果

A Therapeutic Effect observation of 23 G Pars Plana Vitrectomy Assisted by Bevacizumab for Severe Proliferative Diabetic Retinopathy
LI Tao,ZHENG Zhi,ZHENG Bing-qing,ZHAO Shu-zhi,CHEN Wel NI Li-sha.A Therapeutic Effect observation of 23 G Pars Plana Vitrectomy Assisted by Bevacizumab for Severe Proliferative Diabetic Retinopathy[J].Progress in Modern Biomedicine,2013(23):4488-4491.
Authors:LI Tao  ZHENG Zhi  ZHENG Bing-qing  ZHAO Shu-zhi  CHEN Wel NI Li-sha
Institution:(Department of Olohthalmology, Shanghai Jiao Tong University Aftliated First People's Hospital, Shanghai, 200080, China)
Abstract:Objective: In 2011, the number of diabetics in China is up to 92.4 million. As a common complication of diabetes, Di- abetic retinopathy (DR, diabetic retinopathy) has become one of the major causes of adult acquired blindness and its prevalence was 37% in the diabetic population. Traction retinal detachment and vitreous hemorrhage are the Characteristic pathophysiological process of Pro- liferative diabetic retinopathy which is known as high blinding rate and high difficulty of operation, In the present study, the effect of preoperative intravitreal bevacizumab injection (IVB) 3-7 days before 23 G pars plana vitrectomy (PPV) for severe proliferative diabetic retinopathy patients was evaluated. Methods: To retrospect and study the cases. 70 patients 70 eyes with severe proliferative diabetic retinopathy who were divided into group A (23 G pars plana vitrectomy assisted by preoperative intravitreal bevacizumab injection, 21 patients 21 eyes) and group B (23G pars plana vitrectomy,49 patients 49 eyes). Main outcomes measures were visual acuity, operation time, incidence of iatrogenic retinal breaks, endodiathermy, and postoperative bleeding. Results: At 3 months after surgery, the visual acuity of both group improved significantly (P〈0.05). The average operation time is 74 minutes and 85 minutes in group A and group B respectively(P〉0.05), Iatrogenic retinal breaks were reported in 1 case in group A and 16 cases in group B (P〈0.05). Endodiathermy was employed in 3 cases in group A and 25 cases in group B (P〈0.05). Postoperative bleeding was reported in 1 case in group A while 20 cases were reported in group B (P〈0.05). Coulusion: In our 70 severe proliferative diabetic retinopathy patients included retrospective study, we found that preoperative intravitreal 1.25 rag/0.05 ml of bevacizumab injection 3-7 days before surgery had a significant effect to the 23 G three channel pars plana vitrectomy: it could reduce the incidence of iatrogenic retinal break and postoperative bleeding, the em- ployment of endodiathermy.
Keywords:Bevacizumab/avastin  Severe prolierative diabetic retinopathy  Pars plana vitrectomy
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号